Exelixis Inc. (NASDAQ: EXEL) reported subgroup analysis results from its phase 3 CABINET trial showing that Cabometyx reduced the risk ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE